Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774583 | 0.88 | HRH3 (0.57) | SMN1; SMN2MAPTRAB9AHRH3 | |
| SCHEMBL4770900 | 0.86 | HRH3 (0.56) | SMN1; SMN2MAPTRAB9AHRH3KDM4E | |
| SCHEMBL4770797 | 0.85 | HRH3 (0.55) | SMN1; SMN2MAPTRAB9AHRH3KDM4E | |
| SCHEMBL4765222 | 0.85 | HRH3 (0.52) | SMN1; SMN2MAPTRAB9AHRH3 | |
| SCHEMBL4770439 | 0.84 | HRH3 (0.52) | SMN1; SMN2MAPTRAB9AHRH3KDM4E | |
| SCHEMBL4772594 | 0.84 | HRH3 (0.50) | SMN1; SMN2MAPTRAB9AHRH3KDM4E | |
| SCHEMBL4768082 | 0.83 | HRH3 (0.51) | SMN1; SMN2MAPTRAB9AHRH3KDM4E | |
| SCHEMBL4770276 | 0.83 | HRH3 (0.49) | SMN1; SMN2MAPTRAB9AHRH3KDM4E | |
| SCHEMBL4770289 | 0.83 | HRH3 (0.51) | SMN1; SMN2MAPTRAB9AHRH3KDM4E | |
| SCHEMBL4765153 | 0.82 | ADRA1A (0.54) | SMN1; SMN2MAPTRAB9AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| EP-1713778-A1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005058837-A1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | SMN1; SMN2 2487/4885MAPT 405/4885RAB9A 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.